You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
In this book, a distinguished group of clinicians provide straightforward, focused answers to the questions most commonly confronted by a multidisciplinary team when caring for patients with rectal cancer. The format of the book is designed to aid optimal decision making in a multidisciplinary setting with respect to key issues in imaging, radiotherapy, chemotherapy, and surgery, all of which are considered in detail. Helpful guidance is also offered on risk factor identification, pathology procedures and their prognostic value, and multidisciplinary team management. The authors have been carefully selected for their expertise, and most have been involved in the management of the more signif...
This issue of Hematology/Oncology Clinics, Guest Edited by Drs. Edward Snyder and Eric A. Gehrie, with Consulting Editors George P. Canellos and H. Franklin Bunn, will focus on Transfusion Medicine. Topics include, but are not limited to, Pathogen Reduction, Transfusion Reactions-Infectious Complications, Txn Rxn-Non-Infectious Complications, Iron Deficiency and Teen Blood Donors, Advances in RBC Serology, Advances in Immunotherapy, Therapeutic Monoclonal Antibody Effect on RBC Compatibility Testing, Cell Therapy-New Regulations and Standards, Alternatives to Platelet and RBC Transfusions, New Hemostatic Agents, Tx Practices for Children with Cancer, and Relevance of Cold Platelets and WB to the Bleeding Oncology Patient.
The Massachusetts General Hospital (MGH) has a history of excellence and is internationally recognized as a world class medical center, providing quality medical care, advancing medicine through clinical and laboratory research and facilitating the education of exceptional health care professionals. The Massachusetts General Hospital Radiation Oncology Department, staff, residents and fellows, past and present, concur that MGH stands for Man’s Greatest Hospital. This decidedly immodest assessment is widely viewed amongst this group as being manifestly true, and that perception is clearly reflected in a marvelous esprit de corp. Such an unequivocally positive attitude is solidly based on th...
This issue of Hematology/Oncology Clinics, guest edited by Dr. Caron A. Jacobson, with consulting editors George P. Canellos and H. Franklin Bunn, will focus on Non-Hodgkin’s Lymphoma. Topics include, but are not limited to: Ontogeny, Genetics, Molecular Biology and Classification of B and T cell Non-Hodgkin’s Lymphoma; Diffuse large B cell lymphoma and high grade B cell lymphoma; Burkitt lymphoma and other highly aggressive B cell lymphomas; CNS lymphoma; Mantle cell lymphoma; Follicular lymphoma; Marginal zone lymphoma and lymphoplasmacytic lymphoma; Non-cutaneous T cell lymphoma; Cutaneous T cell lymphoma; Transplant and other adoptive immune cell therapies for non-Hodgkin lymphoma; Non-cellular immune therapies for non-Hodgkin’s lymphoma; and Targeting biology in non-Hodgkin’s lymphoma.
This major new work updates and significantly expands The Hastings Center's 1987 Guidelines on the Termination of Life-Sustaining Treatment and Care of the Dying. Like its predecessor, this second edition will shape the ethical and legal framework for decision-making on treatment and end-of-life care in the United States. This groundbreaking work incorporates 25 years of research and innovation in clinical care, law, and policy. It is written for physicians, nurses, and other health care professionals and is structured for easy reference in difficult clinical situations. It supports the work of clinical ethicists, ethics committee members, health lawyers, clinical educators, scholars, and policymakers. It includes extensive practical recommendations. Health care reform places a new set of challenges on decision-making and care near the end of life. The Hastings Center Guidelines are an essential resource.
This issue of the Surgical Oncology Clinics of North America is devoted to Practical Radiation Oncology and is Guest Edited by Dr. Christopher Willett. Articles in this issue include: Radiotherapy After Mastectomy; Contemporary Radiotherapy in Head and Neck Cancer; Image Guided Brachytherapy: An Update for Gynecologic Surgeons; Radiation Therapy in the Current Management of Anal and Rectal Cancer; Novel Approaches to Treatment of Hepatocellular Carcinoma and Hepatic Metastases Using Thermal Ablation and Thermosensitive Liposomes; Contemporary Integration of Radiation Oncology with Surgery as Combined Modality Treatment; Chemoradiation Therapy: Localized Esophageal, Gastric, and Pancreatic Cancer; Stereotactic Body Radiotherapy for the Treatment of Primary and Metastatic Pulmonary Malignancies; Radiotherapy and Radiosurgery for Tumors of the Central Nervous System; Practical Radiation Oncology for Extremity Sarcomas; Radiation Therapy for Prostate Cancer; and Present and Future Innovations in Radiation Oncology.
"Summaries of papers" contained in the journal accompany each issue, 19--
This issue of Hematology/Oncology Clinics, guest edited by Andrew A. Lane, will cover Blastic Plasmacytoid Dendritic Cell Neoplasm. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue include: Clinical Presentation and Pathology, Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA mutations and epigenetics, Cytogenetics of Blastic Plasmacytoid Dendritic Cell Neoplasm, Blastic Plasmacytoid Dendritic Cell Neoplasm Chemotherapy, CD123 and Leukemia Stem Cells, Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm, Immune Therapies Targeting CD123 in Blastic Plasmacytoid Dendritic Cell Neoplasm, Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm, Blastic Plasmacytoid Dendritic Cell Neoplasm in Children, European Perspective, Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm, and Social Media in Blastic Plasmacytoid Dendritic Cell Neoplasm and Other Rare Diseases.
The major features of sickle cell disease in most patients are life-long anemia and the recurrent vaso-occlusion. The pathophysiology of sickle cell disease and hemoglobinopathies, along with the diagnosis and assessment of the risk/benefit ration for particular treatments are discussed.